Pharmacokinetics of a Fixed-Dose Combination of Mitiglinide and Metformin versus Concurrent Administration of Individual Formulations in Healthy Subjects
- 97 Downloads
In the treatment of diabetes mellitus, combined drugs with different mechanisms of action can be effective when adequate glycaemic control is difficult with monotherapy. A fixed-dose combination (FDC) tablet of mitiglinide and metformin has been developed as a second-line treatment for type 2 diabetes.
The objective of this study was to compare the pharmacokinetics and safety of a FDC and a free combination of mitiglinide and metformin in healthy male subjects.
A randomized, open-label, two-period, two-treatment, single-dose, crossover study was conducted in 24 healthy Korean male subjects. In one period, a FDC tablet of mitiglinide and metformin (10 mg/500 mg) was administered, and in the other period, corresponding doses of individual formulations were administered.
Twenty-four subjects were enrolled and 19 subjects completed the study. The geometric mean ratios (90 % confidence interval) of the maximum plasma concentration (Cmax) and area under the plasma concentration–time curve from time zero to the time of the last measurable concentration (AUClast) were 0.9694 (0.8120, 1.1573) and 0.8951 (0.8440, 0.9494) for mitiglinide, and 1.0235 (0.9373, 1.1057) and 1.0542 (0.9697, 1.1460) for metformin, which were within the bioequivalence range. Among the 23 subjects who received study drugs, 15 subjects experienced 34 adverse events (AEs). The most frequently reported AEs were feeling hot and compensatory sweating. There were no serious AEs and no significant differences in the incidence of AEs between the two treatments.
A FDC tablet of mitiglinide and metformin was generally well tolerated in healthy male subjects. Administration of a FDC tablet and concomitant administration of individual formulations did not show significantly different pharmacokinetic profiles.
This study was sponsored by JW Pharmaceutical, Seoul, Korea, and supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health, Welfare and Family Affairs, Republic of Korea (A070001). The authors would like to thank Jeong-Soo Yang (Senior Research Engineer) for conducting the bio-assay in this study. The authors have indicated that they have no other conflicts of interest regarding the content of this article.
- 1.National Diabetes Information Clearinghouse. National Diabetes Statistics, 2011. http://www.diabetes.niddk.nih.gov/dm/pubs/statistics. Accessed 12 Mar 2012
- 2.Standards of medical care in diabetes–2012. Diabetes Care. 2012;35 Suppl 1:S11–63.Google Scholar
- 3.Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.PubMedCrossRefGoogle Scholar
- 5.Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–12.PubMedCrossRefGoogle Scholar
- 11.Cho YM, Koo BK, Son HY, Lee KW, Son HS, Choi DS, et al. Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus. J Diabetes Investig. 2010;1(4):143–8.Google Scholar
- 15.The World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 12 Mar 2012
- 16.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for good clinical practice. http://www.ich.org/LOB/media/MEDIA482.pdf. Accessed 12 May 2012
- 19.Zhang L, Tian Y, Zhang Z, Chen Y. Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;854(1–2):91–8.PubMedGoogle Scholar
- 21.Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed 16 May 2012.
- 22.Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf. Accessed 16 May 2012.